Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1333-1339

  Obama, Kazutaka ^a,b   Satoh, Seiji ^b   Hamamoto, Ryuji ^a   Sakai, Yoshiharu ^b   Nakamura, Yusuke ^a   Furukawa, Yoichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; PROTEIN ANTIBODY; RAD51 ASSOCIATING PROTEIN 1; RAD51 PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; GAMMA IRRADIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DNA PRIMERS; DNA REPAIR; DNA-BINDING PROTEINS; GAMMA RAYS; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 40949086335     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1381     Document Type: Article

References (30)

1. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997;350:1142-3.
2. Kato I, Kuroishi T, Tominaga S. Descriptive epidemiology of subsites of cancers of the liver, biliary tract and pancreas in Japan. Jpn J Clin Oncol 1990;20:232-7.
3. Parkin DM, Ohshima H, Srivatanakul P, Vatanasapt V. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993;2:537-44.
4. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003;37:961-9.
5. Momoi H, Okabe H, Kamikawa T, et al. Comprehensive allelotyping of human intrahepatic cholangiocarcinoma. Clin Cancer Res 2001;7:2648-55.
6. Terada T, Okada Y, Nakanuma Y. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors. Hepatology 1996;23:1341-4.
7. Benckert C, Jonas S, Cramer T, et al. Transforming growth factor h 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocarcinoma cells. Cancer Res 2003;63:1083-92.
8. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 upregulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;36:439-50.
9. Sugawara H, Yasoshima M, Katayanagi K, et al. Relationship between interleukin-6 and proliferation and differentiation in cholangiocarcinoma. Histopathology 1998;33:145-53.
10. Hansel DE, Rahman A, Hidalgo M, et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 2003;163:217-29.
11. Makuuchi M, Belghiti J, Belli G, et al. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg 2003;10:26-30.
12. Javle MM, Tan D, Yu J, et al. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma. Hepatogastroenterology 2004;51:1653-7.
13. Obama K, Ura K, Li M, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology 2005;41:1339-48.
14. Shimokawa T, Furukawa Y, Sakai M, et al. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the β-catenin/T-cell factor complex. Cancer Res 2003;63:6116-20.
15. Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y. Identification of PDZK4, a novel human genewith PDZ domains, that is upregulated in synovial sarcomas. Oncogene 2004;23:5551-7.
16. Hamamoto R, Furukawa Y, Morita M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 2004;6:731-40.
17. Kovalenko OV, Golub EI, Bray-Ward P, Ward DC, Radding CM. A novel nucleic acid-binding protein that interacts with human rad51 recombinase. Nucleic Acids Res 1997;25:4946-53.
18. Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M, Bonner WM. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
19. Song H, Xia SL, Liao C, et al. Genes encoding RAD51AP1, Beclin 1, RbAp48 and aldolase b are up or down-regulated in human primary hepatocellular carcinoma. World J Gastroenterol 2004;10:509-13.
20. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005;43:227-38.
21. Henson SE, Tsai SC, Malone CS, et al. Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks. Mutat Res 2006;601:113-24.
22. Wang Y, Yu Q, Cho AH, et al. Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia 2005;7:748-60.
23. Baumann P, West SC. Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998;23:247-51.
24. Henning W, Sturzbecher HW. Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 2003;193:91-109.
25. Bishop AJ, Schiestl RH. Homologous recombination and its role in carcinogenesis. J Biomed Biotechnol 2002;2:75-85.
26. Arnaudeau C, Lundin C, Helleday T. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J Mol Biol 2001;307:1235-45.
27. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003;22:5612-21.
28. Iwanaga R, Komori H, Ishida S, et al. Identification of novel E2F1 target genes regulated in cell cycle-dependent and independent manners. Oncogene 2006;25:1786-98.
29. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
30. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.